US Dermatology Partners Silver Spring — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2024	Research	$11,893	2
2023	Research	$39,955	3
2022	Research	$126	1
2021	Research	$18,783	7
2020	Research	$60,799	16

Breakdown

Who paid Research payments · program years 2020–2024

AbbVie, Inc. $73,830 21 payments
E.R. Squibb & Sons, L.L.C. $51,847 5 payments
Novartis Pharmaceuticals Corporation $5,878 3 payments

Studies the money was for Research payments · program years 2020–2024

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting $51,847 5 payments
M19-164 $48,224 8 payments
A Phase 3b, Multicenter, Interventional, Open-label Study of Adult Subjects with Moderate to Severe Plaque Psoriasis who have a Suboptimal Response to Secukinumab or Ixekizumab and are Switched to Risankizumab $13,157 6 payments
M16-005 $12,450 7 payments
A Randomized Double Blind Multi Center Study Assessing Short 16 Weeks and Long Term Efficacy Up to 1 Year Safety and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa Sunshine $5,878 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.